- Home
- TIGR vs PHVS Comparison
TIGR vs PHVS Comparison
Compare TIGR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIGR | PHVS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TIGR | PHVS |
|---|---|---|
| Price | $8.75 | $27.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $14.20 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 4.4M | 199.4K |
| Earning Date | 03-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 328.15 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $489,538,356.00 | N/A |
| Revenue This Year | $79.26 | N/A |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | ★ 76.50 | N/A |
| 52 Week Low | $6.38 | $11.51 |
| 52 Week High | $13.55 | $29.80 |
Technical Indicators
Market Signals| Indicator | TIGR | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 60.32 |
| Support Level | $8.53 | $24.51 |
| Resistance Level | $9.38 | $28.50 |
| Average True Range (ATR) | 0.59 | 1.52 |
| MACD | -0.14 | 0.22 |
| Stochastic Oscillator | 7.61 | 86.17 |
Price Performance
Historical ComparisonAbout TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.